One New Star Shines in the MICHELIN Guide Doha’s Second Edition Leave a reply Group Photo MICHELIN Guide unveils its 2026 edition the second since
Group Photo 1 restaurant is promoted to One MICHELIN Star, while 2 others retain their Stars 4 new Bib Gourmand distinctions added, bringing the total to 8 Bib Gourmand restaurants in Doha A total of 44 restaurants are listed in the MICHELIN Guide Doha 2026 selection DOHA, Qatar, Dec. 10, 2025 (GLOBE NEWSWIRE) — Doha’s […]
Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy Leave a reply RICHARDSON, Texas, Dec.
RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled automation, and cloud-native platforms. New […]
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
Recognition follows a vote by professional and active traders, highlighting the critical role of execution quality in institutional-grade trading Best Broker for Execution at the Professional Trader Awards 2025 – EBC Financial Group LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — EBC Financial Group (“EBC”) has been named Best Broker for Execution at the Professional Trader Awards 2025, […]
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated
DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time […]
Digital Realty Announces Access to Oracle Cloud Infrastructure in Singapore via FastConnect Leave a reply SINGAPORE, Dec. 07, 2025 (GLOBE NEWSWIRE) — Digital Realty (NYSE: